WO1996001430A3 - Screening for nuc inhibitors - Google Patents
Screening for nuc inhibitors Download PDFInfo
- Publication number
- WO1996001430A3 WO1996001430A3 PCT/US1995/008328 US9508328W WO9601430A3 WO 1996001430 A3 WO1996001430 A3 WO 1996001430A3 US 9508328 W US9508328 W US 9508328W WO 9601430 A3 WO9601430 A3 WO 9601430A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nuc
- protein
- screening
- agents
- inhibitors
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8503950A JPH10502454A (en) | 1994-07-01 | 1995-06-29 | Screening for NUC inhibitors |
AU29571/95A AU2957195A (en) | 1994-07-01 | 1995-06-29 | Screening for nuc inhibitors |
EP95925440A EP0769146A2 (en) | 1994-07-01 | 1995-06-29 | Screening for nuc inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27063594A | 1994-07-01 | 1994-07-01 | |
US08/270,635 | 1994-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996001430A2 WO1996001430A2 (en) | 1996-01-18 |
WO1996001430A3 true WO1996001430A3 (en) | 1996-10-10 |
Family
ID=23032149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/008328 WO1996001430A2 (en) | 1994-07-01 | 1995-06-29 | Screening for nuc inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0769146A2 (en) |
JP (1) | JPH10502454A (en) |
AU (1) | AU2957195A (en) |
CA (1) | CA2193685A1 (en) |
WO (1) | WO1996001430A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69726182T2 (en) | 1996-12-11 | 2004-08-12 | Dana-Farber Cancer Institute, Inc., Boston | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GROWTH PREVENTION OF TUMOR CELLS CONTAINING A PPAR-GAMMA AGONIST AND A MAP KINASE INHIBITOR |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
AU4154799A (en) * | 1998-06-02 | 1999-12-20 | Arthromics Plc | Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
AU2005287215B2 (en) | 2004-09-16 | 2011-04-07 | Merck Sharp & Dohme Corp. | Compounds for the treatment of dyslipidemia and other lipid disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011974A2 (en) * | 1993-10-22 | 1995-05-04 | Ligand Pharmaceuticals, Inc. | Human peroxisome proliferator activated receptor |
WO1995018533A1 (en) * | 1994-01-04 | 1995-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compounds affecting adipocyte differentiation and obesity |
WO1996001317A2 (en) * | 1994-07-01 | 1996-01-18 | The Salk Institute For Biological Studies | Mammalian peroxisome proliferator-activated receptors and uses thereof |
-
1995
- 1995-06-29 WO PCT/US1995/008328 patent/WO1996001430A2/en not_active Application Discontinuation
- 1995-06-29 EP EP95925440A patent/EP0769146A2/en not_active Withdrawn
- 1995-06-29 CA CA002193685A patent/CA2193685A1/en not_active Abandoned
- 1995-06-29 JP JP8503950A patent/JPH10502454A/en active Pending
- 1995-06-29 AU AU29571/95A patent/AU2957195A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011974A2 (en) * | 1993-10-22 | 1995-05-04 | Ligand Pharmaceuticals, Inc. | Human peroxisome proliferator activated receptor |
WO1995018533A1 (en) * | 1994-01-04 | 1995-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compounds affecting adipocyte differentiation and obesity |
WO1996001317A2 (en) * | 1994-07-01 | 1996-01-18 | The Salk Institute For Biological Studies | Mammalian peroxisome proliferator-activated receptors and uses thereof |
Non-Patent Citations (2)
Title |
---|
A. SCHMIDT ET AL.: "Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.", MOLECULAR ENDOCRINOLOGY, vol. 6, no. 10, 1992, WASHINGTON DC USA, pages 749 - 784, XP000579262 * |
F. CHEN ET AL.: "Identification of two mPPAR related receptors and evidence for the existence of five subfamily members", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 196, no. 2, 1993, NEW YORK NY USA, pages 671 - 677, XP000577084 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996001430A2 (en) | 1996-01-18 |
AU2957195A (en) | 1996-01-25 |
JPH10502454A (en) | 1998-03-03 |
EP0769146A2 (en) | 1997-04-23 |
CA2193685A1 (en) | 1996-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU9262598A (en) | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders | |
ATE321548T1 (en) | USE OF STATIN TO TREAT SKIN DISEASES | |
ZA971937B (en) | Combinations for treatment of proliferative diseases. | |
DE69936335D1 (en) | USE OF MORPHOLINOL FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISORDERS | |
GB9323165D0 (en) | Compounds | |
AU7321598A (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
ATE527022T1 (en) | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT AND PREVENTION OF TUMORS, TUMOR-DEPENDENT DISEASES AND CACHEXIA | |
EE9900036A (en) | Novel compounds and compositions for the treatment of diseases associated with tryptase activity | |
EP0909561A3 (en) | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | |
DE69635708D1 (en) | TETRANDRIN FOR THE TREATMENT OF EYE IGNITIONS | |
WO1997003188A3 (en) | Use of mp52 or mp121 for treating and preventing diseases of the nervous system | |
ATE201992T1 (en) | CARBOSTYRIL DERIVATIVE FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES | |
MA25404A1 (en) | METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS. | |
ATE214272T1 (en) | TOPICAL USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT EYE PAIN | |
DE69638281D1 (en) | Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for the treatment of bronchial hyperreactivity | |
ATE173620T1 (en) | USE OF AN ANTAGONIST OF TNF-ALPHA FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN | |
WO2001021647A3 (en) | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases | |
WO1996001430A3 (en) | Screening for nuc inhibitors | |
DE69729735D1 (en) | USE OF BENZOPYRANOLS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
DE59511032D1 (en) | USE OF NOTOGINSENOSIDE R1 FOR THE TREATMENT OF ENDOTOXIN SHOCK OR HEART DISEASES | |
DE69735417D1 (en) | 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS | |
DE69822297D1 (en) | TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
DE59704933D1 (en) | Use of PHMB for the treatment of tumor diseases | |
DE69924284D1 (en) | USE OF STIMULATORS OF NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEEGENERATIVE OPHTHALMIC DISEASES | |
DE60034110D1 (en) | USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2193685 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995925440 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925440 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995925440 Country of ref document: EP |